Survey of Optical Values of the Breast Using Radiation-Free Pressure-Free Optical Scanning
- Conditions
- Breast LesionsBreast CystEarly-Stage Breast CancerBenign Growth, Breast
- Registration Number
- NCT00671385
- Lead Sponsor
- Spectros Corporation
- Brief Summary
The purposes of this study is to establish normal optical values of breast tissue in the general population. This will allow for establishing normals for breast composition, and is expected to be useful in the classification of breast lesions into groups such as cysts, benign growths, inflammatory lesions, and possibly early breast cancer.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- Female
- Target Recruitment
- 2000
Inclusion Criteria
- You must be female
- You must be 21 to 50 years old
- You must not have or have had breast cancer.
- You must not have or have had breast implants or breast surgery
- You must not have had a breast biopsy or injury, or a breast infection, in 90 days.
Exclusion Criteria
- Any one or more of the above conditions not met
- Lack of informed consent
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Optical normals for the breast for a variety of conditions 3 years
- Secondary Outcome Measures
Name Time Method Diagnostic compositional standards for (a) diagnosis of a condition such as cyst, benign growth, inflammation, and/or (b) referral for additional evaluation of a region of interest. 1 year
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie optical scanning for breast lesion classification in NCT00671385?
How does radiation-free optical scanning compare to mammography in early breast cancer detection?
Which biomarkers correlate with optical values in benign versus malignant breast lesions using Spectros Corporation's technology?
What adverse events are associated with pressure-free optical scanning in breast cancer screening?
Are there combination approaches integrating optical scanning with other breast cancer diagnostic modalities like MRI or ultrasound?
Trial Locations
- Locations (1)
Spectros Corporation
🇺🇸Portola Valley, California, United States
Spectros Corporation🇺🇸Portola Valley, California, United StatesLizzy van Thillo, AAContact650-851-4040lizzy@spectros.comCarrie Bomarito, RNContact640-851-4040info@spectros.com